Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $57.10 USD
Change Today +1.43 / 2.57%
Volume 608.2K
RDY On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 6:40 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

8-2-337, Road No. 3

Banjara Hills

Hyderabad, 500034

India

Phone: 91 40 4900 2900

Fax: 91 40 4900 2999

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company. The company has a presence in markets, such as the United States, the United Kingdom and Germany, as well as other markets, such as India, Russia, Venezuela, Romania, South Africa and certain countries of the former Soviet Union. Segments The company operates in three business segments: Global Generics segment, which includes its branded and unbranded prescription and over-the-counter (OTC) drug products business, as well as its biologics business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its Active Pharmaceutical Ingredients (API) business and Custom Pharmaceutical Services (CPS) business; and Proprietary Products segment, which consists of its Differentiated Formulations business, its new chemical entities business, and its dermatology focused specialty business operated through Promius Pharma LLC (Promius Pharma). Global Generics Segment This segment offers generic pharmaceutical. India: In India, the company’s key therapeutic categories include gastro-intestinal, cardiovascular, pain management and oncology. The company is also increasing its presence in the niche areas of dermatology, urology, and nephrology. As of March 31, 2014, the company had a total of 277 branded products in India. IMS Health is a provider of market research to the Indian pharmaceutical industry. Sales, Marketing and Distribution Network: The company generates demand for its products through its 4,863 sales representatives and front line managers, who frequently visit doctors to detail its related product portfolio. The company sells its products primarily through clearing and forwarding agents to approximately 2,500 wholesalers who decide which brands to buy based on demand. The wholesalers pay for the company’s products in an agreed credit period and in turn sell these products to retailers. Its clearing and forwarding agents are responsible for transporting its products to the wholesalers. Competition: The company’s principal competitors in the Indian market include Cipla Limited; Ranbaxy Laboratories Limited; GlaxoSmithKline Pharmaceuticals Limited; Cadila Healthcare Limited; Sun Pharmaceutical Industries Limited; Alkem Limited; Mankind Pharma Limited; Pfizer Limited; Abbott India; Lupin Limited; Aristo Pharma Limited; Intas Pharma; Sanofi India Limited; and Emcure Pharmaceuticals Limited. Russia and other Countries of the former Soviet Union Russia: The company’s major brands include Nise, Omez, Ketorol and Cetrine. The company’s strategy in Russia is to focus on the gastro-intestinal, pain management, anti-infectives, respiratory, oncology and cardiovascular therapeutic areas. Its focus is on building brands in these therapeutic areas in prescription, OTC and hospital sales. Other Countries of the former Soviet Union: The company operates in other countries of the former Soviet Union, including Ukraine, Kazakhstan, Belarus and Uzbekistan. Competition: The company’s principal competitors in the Russian market include Berlin Chemi AG; Gedeon Richter Limited; Krka d.d.; Teva Pharmaceutical Industries Ltd.; Lek-Sandoz Pharmaceuticals (an affiliate of Novartis Pharma A.G.); Ranbaxy Laboratories Limited; Nycomed International Management GmbH; and Zentiva N.V. (an affiliate of Sanofi-Aventis S.A.). North America (the United States and Canada) In the United States, the company sells generic drugs that are the chemical and therapeutic equivalents of reference branded drugs, typically sold under their generic chemical names at prices below those of their brand drug equivalents. Strategy The company’s strategy to achieve this core purpose is to combine industry-leading science and technology, product offerings and customer service with execution excellence. Sales, Marketing and Distribution Network Dr. Reddy’s Laboratories, Inc., the company’s wholly-owned subsidiary in New Jersey, United States, is primarily engaged in the marketing of its generic products in the United States. The company has its own sales and marketing team to market these generic products. Its key acco

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDY:US $57.10 USD +1.43

RDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,742 INR +45.70
Cipla Ltd/India 712.45 INR +10.25
Croda International PLC 2,739 GBp +14.00
Lonza Group AG SFr.121.50 CHF -1.50
Symrise AG €58.70 EUR -0.50
View Industry Companies
 

Industry Analysis

RDY

Industry Average

Valuation RDY Industry Range
Price/Earnings 27.6x
Price/Sales 4.2x
Price/Book 5.7x
Price/Cash Flow 27.5x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DOCTOR REDDY'S LAB-ADR, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.